Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
PaperCitations, authors & open-access status
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 964 citations, 2016 year and green oa status.
964
Citations
2016
Year
green
OA Status